Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Translational Metabolism
Published in: Clinical Reviews in Bone and Mineral Metabolism 1-4/2023

29-04-2023 | Insulins | Review Article

Type 2 Diabetes and Bone Disease

Authors: Norma Lopez, Sara M. Cohen, Maryann Emanuele

Published in: Clinical & Translational Metabolism | Issue 1-4/2023

Login to get access

Abstract

Diabetes and osteoporosis are age-related conditions contributing to the burgeoning burden of health care as life expectancy increases. Over the past 30 years, evidence has emerged indicating that these two conditions are related. Diabetes is well recognized to affect bone health, contributing to decreased bone formation, increased bone marrow adiposity, and heightened risk of fracture. Age-related inflammation and oxidative stress promote the development of osteoporosis primarily by reducing bone formation, and they are augmented in diabetes. There is an association between reduced bone remodeling and increased incidence of type 2 diabetes mellitus (T2DM). Although both men and women are affected, more research on this relationship has been conducted in older women, likely due to a higher burden of disease. Mounting evidence demonstrates the influence of bone remodeling on glucose regulation via bone-derived factors. These factors include fibroblast growth factor 23 (FGF-23) and osteocalcin, which affect pancreatic beta cell proliferation; insulin expression and secretion; and storage and release of glucose from the liver, skeletal muscle, and adipose tissue. This review will highlight the inter-connectivity of diabetes and osteoporosis, focusing on the clinical relevance of diagnosing and treating bone loss early and appropriately in individuals with diabetes.
Literature
1.
Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet. 2016;387:1513–30.CrossRef
2.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–75.PubMedCrossRef
3.
Massera D, Biggs ML, Walker MD, Mukamal KJ, Ix JH, Djousse L, et al. Biochemical markers of bone turnover and risk of incident diabetes in older women: the cardiovascular health study. Diabetes Care. 2018;41:1901–8.PubMedPubMedCentralCrossRef
4.
Bonnet N. Bone-derived factors: a new gateway to regulate glycemia. Calcif Tissue Int. 2017;100:174–83.PubMedCrossRef
5.
Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:32–8.PubMedCrossRef
6.
Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91:3404–10.PubMedCrossRef
7.
Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.PubMedCrossRef
8.
Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27:219–28.PubMedCrossRef
9.
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427–44.PubMedCrossRef
10.
Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27:301–8.PubMedCrossRef
11.
Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231–7.PubMedCrossRef
12.
13.
Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image: TRABECULAR BONE SCORE. J Bone Miner Res. 2014;29:518–30.PubMedCrossRef
14.
Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi M-L, Cooper C, et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone. 2015;78:216–24.PubMedPubMedCentralCrossRef
15.
McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX: TBS IN FRACTURE RISK PREDICTION AND RELATIONSHIP TO FRAX. J Bone Miner Res. 2016;31:940–8.PubMedCrossRef
16.
Leslie WD, Aubry-Rozier B, Lamy O, Hans D, for the Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013;98:602–9.PubMedCrossRef
17.
Dhaliwal R, Cibula D, Ghosh C, Weinstock RS, Moses AM. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int. 2014;25:1969–73.PubMedCrossRef
18.
Kim JH, Choi HJ, Ku EJ, Kim KM, Kim SW, Cho NH, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015;100:475–82.PubMedCrossRef
19.
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y. Scientific advisory Board of the European Society for clinical and economic aspects of osteoporosis (ESCEO) and the committees of scientific advisors and National Societies of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3–44.PubMedCrossRef
20.
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26:1–46.PubMedCrossRef
21.
Shepherd JA, Schousboe JT, Broy SB, Engelke K, Leslie WD. Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD. J Clin Densitom. 2015;18:274–86.PubMedCrossRef
22.
Manske SL, Zhu Y, Sandino C, Boyd SK. Human trabecular bone microarchitecture can be assessed independently of density with second generation HR-pQCT. Bone. 2015;79:213–21.PubMedCrossRef
23.
24.
Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res. 2016;4:16001.PubMedPubMedCentralCrossRef
25.
Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28:313–24.PubMedCrossRef
26.
Dhaliwal R, Rosen C. Type 2 diabetes and aging: a not so sweet scenario for bone. Horm Metab Res. 2016;48:771–8.PubMedCrossRef
27.
Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:5045–55.PubMedPubMedCentralCrossRef
28.
Dobnig H, Piswanger-Sölkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006;91:3355–63.PubMedCrossRef
29.
Ardawi M-SM, Akhbar DH, AlShaikh A, Ahmed MM, Qari MH, Rouzi AA, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56:355–62.PubMedCrossRef
30.
Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:1277–84.PubMedCrossRef
31.
Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, et al. Sclerostin levels associated with inhibition of the wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:3744–50.PubMedCrossRef
32.
Krakauer JC, Mckenna MJ, Fenn Buderer N, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44:775–82.PubMedCrossRef
33.
34.
Farr JN, Drake MT, Amin S, Melton LJ, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes: BONE QUALITY IN WOMEN WITH T2D. J Bone Miner Res. 2014;29:787–95.PubMedCrossRef
35.
Li Z, Frey JL, Wong GW, Faugere M-C, Wolfgang MJ, Kim JK, et al. Glucose transporter-4 facilitates insulin-stimulated glucose uptake in osteoblasts. Endocrinology. 2016;157:4094–103.PubMedPubMedCentralCrossRef
36.
37.
38.
Komarova SV, Ataullakhanov FI, Globus RK. Bioenergetics and mitochondrial transmembrane potential during differentiation of cultured osteoblasts. Am J Physiol-Cell Physiol. 2000;279:C1220–9.PubMedCrossRef
39.
40.
41.
Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, et al. High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone. 2008;42:1122–30.PubMedPubMedCentralCrossRef
42.
Lemma S, Sboarina M, Porporato PE, Zini N, Sonveaux P, Di Pompo G, et al. Energy metabolism in osteoclast formation and activity. Int J Biochem Cell Biol. 2016;79:168–80.PubMedCrossRef
43.
Xu F, Ye Y, Dong Y, Guo F, Chen A, Huang S. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technolog Med Sci. 2013;33:244–9.PubMedCrossRef
44.
Kayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S, et al. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007;22:560–8.PubMedCrossRef
45.
Ding K-H, Wang Z-Z, Hamrick MW, Deng Z-B, Zhou L, Kang B, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun. 2006;340:1091–7.PubMedCrossRef
46.
Reni C, Mangialardi G, Meloni M, Madeddu P. Diabetes stimulates osteoclastogenesis by acidosis-induced activation of transient receptor potential cation channels. Sci Rep. 2016;6:30639.PubMedPubMedCentralCrossRef
47.
Bai X, Lu D, Bai J, Zheng H, Ke Z, Li X, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-κB. Biochem Biophys Res Commun. 2004;314:197–207.PubMedCrossRef
48.
Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24:702–9.PubMedCrossRef
49.
Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17:1514–23.PubMedCrossRef
50.
Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands J-L, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol. 2008;7:29.PubMedPubMedCentralCrossRef
51.
Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am. 2013;42:697–719.PubMedCrossRef
52.
Brings S, Fleming T, Freichel M, Muckenthaler M, Herzig S, Nawroth P. Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. Int J Mol Sci. 2017;18:984.PubMedPubMedCentralCrossRef
53.
54.
55.
Farlay D, Armas LA, Gineyts E, Akhter MP, Recker RR, Boivin G. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus: TYPE 1 DIABETES AND HUMAN BONE MATRIX. J Bone Miner Res. 2016;31:190–5.PubMedCrossRef
56.
Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380–6.PubMedPubMedCentralCrossRef
57.
Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu J-L, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771–81.PubMedPubMedCentralCrossRef
58.
Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone. 1998;22:17–23.PubMedCrossRef
59.
McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol. 2001;38:113–22.PubMedCrossRef
60.
Miyake H, Kanazawa I, Sugimoto T. Decreased serum insulin-like growth factor-I is a risk factor for non-vertebral fractures in diabetic postmenopausal women. Intern Med. 2017;56:269–73.PubMedPubMedCentralCrossRef
61.
Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2007;18:1675–81.PubMedCrossRef
62.
Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res. 1996;11:931–7.PubMedCrossRef
63.
Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res. 1997;12:439–46.PubMedCrossRef
64.
Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem. 2007;282:5691–703.PubMedCrossRef
65.
66.
Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25:2185–97.PubMedCrossRef
67.
68.
Cai Z, Yang B, Shi Y, Zhang W, Liu F, Zhao W, et al. High glucose downregulates the effects of autophagy on osteoclastogenesis via the AMPK/mTOR/ULK1 pathway. Biochem Biophys Res Commun. 2018;503:428–35.PubMedCrossRef
69.
Catalfamo D, Britten T, Storch D, Calderon N, Sorenson H, Wallet S. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. Oral Dis. 2013;19:303–12.PubMedPubMedCentralCrossRef
70.
Thrailkill KM, Lumpkin CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol-Endocrinol Metab. 2005;289:E735–45.PubMedCrossRef
71.
Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309–19.PubMedPubMedCentralCrossRef
72.
Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296–308.PubMedPubMedCentralCrossRef
73.
74.
Ferro Y, Russo C, Russo D, Gazzaruso C, Coppola A, Gallotti P, et al. Association between low C-peptide and fragility fractures in postmenopausal women without diabetes. J Endocrinol Invest. 2017;40:1091–8.PubMedCrossRef
75.
Pujia A, Gazzaruso C, Montalcini T. An update on the potential role of C-peptide in diabetes and osteoporosis. Endocrine. 2017;58:408–12.PubMedCrossRef
76.
Bartell SM, Kim H-N, Ambrogini E, Han L, Iyer S, Serra Ucer S, et al. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014;5:3773.PubMedCrossRef
77.
78.
Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434:514–20.PubMedCrossRef
79.
Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305–17.PubMedCrossRef
80.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay. Cell. 2000;100:197–207.PubMedCrossRef
81.
82.
Reid IR, Richards JB. Adipokine effects on bone. Clin Rev Bone Miner Metab. 2009;7:240–8.CrossRef
83.
Ozata M. Different presentation of bone mass in mice and humans with congenital leptin deficiency. J Clin Endocrinol Metab. 2002;87:951–951.PubMedCrossRef
84.
Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women: Leptin, BMD and vertebral fractures. Clin Endocrinol (Oxf). 2001;55:341–7.PubMedCrossRef
85.
Mpalaris V, Anagnostis P, Anastasilakis AD, Goulis DG, Doumas A, Iakovou I. Serum leptin, adiponectin and ghrelin concentrations in post-menopausal women: Is there an association with bone mineral density? Maturitas. 2016;88:32–6.PubMedCrossRef
86.
Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes 1. Endocrinology. 1999;140:1630–8.PubMedCrossRef
87.
Pal China S, Sanyal S, Chattopadhyay N. Adiponectin signaling and its role in bone metabolism. Cytokine. 2018;112:116–31.PubMedCrossRef
88.
89.
Dong X, Bi L, He S, Meng G, Wei B, Jia S, et al. FFAs-ROS-ERK/P38 pathway plays a key role in adipocyte lipotoxicity on osteoblasts in co-culture. Biochimie. 2014;101:123–31.PubMedCrossRef
90.
Kushwaha P, Wolfgang MJ, Riddle RC. Fatty acid metabolism by the osteoblast. Bone. 2018;115:8–14.PubMedCrossRef
91.
92.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102.PubMedCrossRef
93.
Aroda VR. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018;20:22–33.PubMedCrossRef
94.
Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, et al. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int. 2018;29:2639–44.PubMedCrossRef
95.
96.
Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48:107–15.PubMedCrossRef
97.
Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?: GLP-1 RA: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016;81:78–88.PubMedCrossRef
98.
Driessen JHM, van Onzenoort HAW, Starup-Linde J, Henry R, Burden AM, Neef C, et al. Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. 2015;97:506–15.PubMedPubMedCentralCrossRef
99.
Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int. 2009;84:453–61.PubMedCrossRef
100.
101.
Yu J, Shi Y-C, Ping F, Li W, Zhang H-B, He S-L, et al. Liraglutide inhibits osteoclastogenesis and improves bone loss by downregulating Trem2 in female type 1 diabetic mice: findings from transcriptomics. Front Endocrinol. 2021;12:763646.CrossRef
102.
Egger A, Kraenzlin ME, Meier C. Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health. Curr Osteoporos Rep. 2016;14:345–50.PubMedCrossRef
103.
Mamza J, Marlin C, Wang C, Chokkalingam K, Idris I. DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;116:288–98.PubMedCrossRef
104.
Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, et al. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial: JOSSE et al. Diabetes Obes Metab. 2017;19:78–86.PubMedCrossRef
105.
Mu W, Wang Z, Ma C, Jiang Y, Zhang N, Hu K, et al. Metformin promotes the proliferation and differentiation of murine preosteoblast by regulating the expression of sirt6 and oct4. Pharmacol Res. 2018;129:462–74.PubMedCrossRef
106.
107.
Yang X, Kord-Varkaneh H, Talaei S, Clark CCT, Zanghelini F, Tan SC, et al. The influence of metformin on IGF-1 levels in humans: a systematic review and meta-analysis. Pharmacol Res. 2020;151:104588.PubMedCrossRef
108.
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care. 2008;31:845–51.PubMedCrossRef
109.
Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012;55:2929–37.PubMedPubMedCentralCrossRef
110.
Salari-Moghaddam A, Sadeghi O, Keshteli AH, Larijani B, Esmaillzadeh A. Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies. Osteoporos Int. 2019;30:1167–73.PubMedCrossRef
111.
Oh TK, Song I-A. Metformin therapy and hip fracture risk among patients with type II diabetes mellitus: a population-based cohort study. Bone. 2020;135:115325.PubMedCrossRef
112.
113.
114.
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of Thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820.PubMedCrossRef
115.
Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am. 2015;99:87–106.PubMedCrossRef
116.
Ma P, Gu B, Xiong W, Tan B, Geng W, Li J, et al. Glimepiride promotes osteogenic differentiation in rat osteoblasts via the PI3K/Akt/eNOS pathway in a high glucose microenvironment. Beltrami AP, editor. PLoS ONE. 2014;9:e112243.PubMedPubMedCentralCrossRef
117.
Guney E, Kisakol G, Oge A, Yilmaz C, Kabalak T. Effects of insulin and sulphonylureas on insulin-like growth factor-I levels in streptozotocin-induced diabetic rats. Neuro Endocrinol Lett. 2002;23:437–9.PubMed
118.
Tao Y, E M, Shi J, Zhang Z. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study. Aging Clin Exp Res. 2021;33:2133–9.PubMedCrossRef
119.
Starup-Linde J, Gregersen S, Frost M, Vestergaard P. Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes. Bone. 2017;95:136–42.PubMedCrossRef
120.
Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36:194–213.PubMedCrossRef
121.
122.
Mughal A, Kumar D, Vikram A. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling. Eur J Pharmacol. 2015;768:217–25.PubMedCrossRef
123.
Stage TB, Christensen M-MH, Jørgensen NR, Beck-Nielsen H, Brøsen K, Gram J, et al. Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone. 2018;112:35–41.PubMedCrossRef
124.
Ma R, Wang L, Zhao B, Liu C, Liu H, Zhu R, et al. Diabetes perturbs bone microarchitecture and bone strength through regulation of Sema3A/IGF-1/β-Catenin in rats. Cell Physiol Biochem. 2017;41:55–66.PubMedCrossRef
125.
Degen AS, Krynytska IY, Kamyshnyi AM. Changes in the transcriptional activity of the entero-insular axis genes in streptozotocin-induced diabetes and after the administration of TNF-α non-selective blockers. Endocr Regul. 2020;54:160–71.PubMedCrossRef
126.
Lee RH, Sloane R, Pieper C, Lyles KW, Adler RA, Houtven C, et al. Glycemic control and insulin treatment alter fracture risk in older men with type 2 diabetes mellitus. J Bone Miner Res. 2019;34:2045–51.PubMedCrossRef
127.
Losada-Grande E, Hawley S, Soldevila B, Martinez-Laguna D, Nogues X, Diez-Perez A, et al. Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort analysis. Sci Rep. 2017;7:3781.PubMedPubMedCentralCrossRef
128.
Corrao G, Monzio Compagnoni M, Ronco R, Merlino L, Ciardullo S, Perseghin G, et al. Is switching from oral antidiabetic therapy to insulin associated with an increased fracture risk? Clin Orthop. 2020;478:992–1003.PubMedCrossRef
129.
Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone. 2016;82:93–100.PubMedCrossRef
Metadata
Title
Type 2 Diabetes and Bone Disease
Authors
Norma Lopez
Sara M. Cohen
Maryann Emanuele
Publication date
29-04-2023
Publisher
Springer US
Published in
Clinical & Translational Metabolism / Issue 1-4/2023
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-023-09288-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits